Newron Pharmaceuticals SpA
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Brain Health
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing innovative therapies for diseases of the central and peripheral nervous system. Headquartered near Milan, Italy, with a subsidiary in New Jersey, the company has a strong track record of advancing neuroscience treatments from discovery through to commercialization. Its lead compound, evenamide, is a first-in-class glutamate modulator currently in the global Phase III ENIGMA-TRS program as an add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding patients. Clinical data to date show significant and increasing efficacy over time, along with a favorable safety profile uncommon among antipsychotics. Newron has partnerships with EA Pharma (Eisai group) and Myung In Pharm for Asia. Its marketed product, Xadago® (safinamide) for Parkinson’s disease, is approved in multiple regions and commercialized with partners including Zambon, Supernus, and Meiji Seika.
Company HQ City:
20091 Bresso (Mi)
Company HQ State:
Italy
Company HQ Country:
Italy
Year Founded:
1999
Lead Product in Development:
evenamide
CEO
Stefan Weber
Development Phase of Lead Product
Phase III
Exchange
CHF
Ticker
SIX: NWRN, XETRA: NP5
When you expect your next catalyst update?
Q4 2026
What is your next catalyst (value inflection) update?
Phase III data readout
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}